Charles A. Leath III, MD
Associate Professor
University of Alabama at Birmingham
Women & Infants Center, 1700 6th Ave South
Room 10250
Birmingham,
AL
USA
35233
Papers:
15
PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: can we afford it?
139
Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma
199
Are hospital readmissions an accurate measure of quality cancer care in gynecologic oncology patients?
251
Comprehensive genetic testing: the next generation in an ovarian cancer risk assessment clinic
312
Prospective correlation of multinational association for supportive care in cancer risk index score with outcomes in neutropenic fever
343
What is the impact of distance from a comprehensive cancer center on survival in patients with cervical cancer?
393
Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?
425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
426
Genetic counseling and evaluation of BRCA mutations in an African American female population in the Deep South
434
Multi-institutional validation of decreased survival with venous thromboembolism in ovarian clear cell carcinoma
Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial